touchPODCAST

touchMDT for touchIMMUNOLOGY

touchMDT for touchIMMUNOLOGY

Pruritus in PBC and me: The patient experience

Listen to experts Prof. Gideon Hirschfield and Prof. Sonja Ständer, plus patient advocate Mrs Collette Thain MBE, explore the burden of cholestatic pruritus in patients with primary biliary cholangitis (PBC).

touchCLINICAL PERSPECTIVES for touchRESPIRATORY

Join Dr Helena Yu, course director, as she discusses the unmet needs and research opportunities in metastatic EGFR-mutant and wildtype NSCLC. By exploring key clinical trial data alongside real-world patient cases, healthcare providers will gain valuable insights into how to effectively implement these findings in clinical practice. In addition, the clinical experts highlight the critical role of biomarker testing in NSCLC for personalizing treatment plans and discuss the importance of patient support in navigating the NSCLC treatment journey.

Course director

Dr Helena Yu, Memorial Sloan Kettering Cancer Center New York, NY, USA

The clinical experts

Dr Aaron Lisberg, University of California Los Angeles (UCLA), Los Angeles, CA, USA

Dr Antonio Passaro, European Institute of Oncology, Milan, Italy

Dr Sara Pilotto, University of Verona, Verona, Italy

Ms Jackie Fenemore, Christie NHS Foundation Trust, Manchester, UK

Prof. Egbert Smit, Leiden University Medical Center, Leiden, The Netherlands and Netherlands Cancer Institute, Amsterdam, The Netherlands

Modules

Module 1: EGFR-mutant NSCLC: Navigating the horizon in EGFR-mutant NSCLC (timestamp: 0:00 - 32:33)

Module 2: EGFR-wildtype NSCLC: Advances in the treatment landscape (timestamp: 32:34 - 01:06:10)

Module 3: Bringing it together (timestamp: 01:06:10 - 01:43:40)

This touchPODCAST is for HCPs only.

This activity is funded by an educational grant from AstraZeneca Ltd. 

This medical education is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website:  

https://touchoncologyime.org/egfr-and-wildtype-late-stage-nsclc-management/

touchCLINICAL PERSPECTIVES for touchONCOLOGY

Join Dr Helena Yu, course director, as she discusses the unmet needs and research opportunities in metastatic EGFR-mutant and wildtype NSCLC. By exploring key clinical trial data alongside real-world patient cases, healthcare providers will gain valuable insights into how to effectively implement these findings in clinical practice. In addition, the clinical experts highlight the critical role of biomarker testing in NSCLC for personalizing treatment plans and discuss the importance of patient support in navigating the NSCLC treatment journey.

Course director

Dr Helena Yu, Memorial Sloan Kettering Cancer Center New York, NY, USA

The clinical experts

Dr Aaron Lisberg, University of California Los Angeles (UCLA), Los Angeles, CA, USA

Dr Antonio Passaro, European Institute of Oncology, Milan, Italy

Dr Sara Pilotto, University of Verona, Verona, Italy

Ms Jackie Fenemore, Christie NHS Foundation Trust, Manchester, UK

Prof. Egbert Smit, Leiden University Medical Center, Leiden, The Netherlands and Netherlands Cancer Institute, Amsterdam, The Netherlands

Modules

Module 1: EGFR-mutant NSCLC: Navigating the horizon in EGFR-mutant NSCLC (timestamp: 0:00 - 32:33)

Module 2: EGFR-wildtype NSCLC: Advances in the treatment landscape (timestamp: 32:34 - 01:06:10)

Module 3: Bringing it together (timestamp: 01:06:10 - 01:43:40)

This touchPODCAST is for HCPs only.

This activity is funded by an educational grant from AstraZeneca Ltd. 

This medical education is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website:  

touchPANEL DISCUSSION for touchRESPIRATORY

Listen to three experts as they explore tissue-agnostic HER2 targeting in solid tumours, the latest clinical trial data for approved and emerging HER2-targeted therapies in NSCLC, and best practices for testing for HER2 alterations in NSCLC.  

The experts

• Dr Razelle Kurzrock - Medical Oncologist, Medical College of Wisconsin, Milwaukee, WI, USA

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from AstraZeneca, and is jointly provided by USF Health and touchIME. 

For further information visit our website: https://touchrespiratoryime.org/her2_in_solid_tumours_and_nsclc/

touchPANEL DISCUSSION for touchONCOLOGY

Listen to three experts as they explore tissue-agnostic HER2 targeting in solid tumours, the latest clinical trial data for approved and emerging HER2-targeted therapies in NSCLC, and best practices for testing for HER2 alterations in NSCLC.  

The experts

• Dr Razelle Kurzrock - Medical Oncologist, Medical College of Wisconsin, Milwaukee, WI, USA

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from AstraZeneca, and is jointly provided by USF Health and touchIME. 

For further information visit our website: https://touchoncologyime.org/her2_in_solid_tumours_and_nsclc/

touchCONGRESS for touchHAEMATOLOGY

Listen to immune thrombocytopenia (ITP) expert Dr Vickie McDonald review key data presented at the European Hematology Association (EHA) and International Society on Thrombosis and Haemostasis (ISTH) 2024 congresses on the impact and current and future management of ITP. She is joined by two additional leading ITP experts, Prof. James Bussel and Prof. Waleed Ghanima, to discuss how these data may apply in clinical practice.

Overview 

• Data reviews with Dr McDonald

Clinical themes

1. How does ITP impact the patient and their quality of life?

The internationally renowned ITP expert faculty

• Dr Vickie McDonald: London, UK

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Sanofi and is jointly provided by USF Health and touchIME.

For further information visit our website: 

touchCONGRESS for touchONCOLOGY

Listen to immune thrombocytopenia (ITP) expert Dr Vickie McDonald review key data presented at the European Hematology Association (EHA) and International Society on Thrombosis and Haemostasis (ISTH) 2024 congresses on the impact and current and future management of ITP. She is joined by two additional leading ITP experts, Prof. James Bussel and Prof. Waleed Ghanima, to discuss how these data may apply in clinical practice.

Overview 

• Data reviews with Dr McDonald

Clinical themes

1. How does ITP impact the patient and their quality of life?

The internationally renowned ITP expert faculty

• Dr Vickie McDonald: London, UK

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Sanofi and is jointly provided by USF Health and touchIME.

For further information visit our website: 

touchPANEL DISCUSSION for touchENDOCRINOLOGY

Listen to a panel of experts discuss the benefits of CGM in patients with T2D, strategies to overcome the barriers to its uptake and how to best support patients in implementing CGM.

The experts

• Prof. Stewart Harris, Western University,  London, Ontario, Canada,

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Abbott Diabetes Care Inc. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: 

touchFOCUS for touchONCOLOGY

Listen to Prof. Hans Hammers as he answers a series of questions on the application of prognostic markers and clinical data within the multidisciplinary team to personalize care for patients with early stage through to advanced and metastatic RCC. In addition, he responds to questions on the use of effective communication strategies and shared decision-making when managing diverse and/or underserved populations with RCC.

The expert

• Prof. Hans Hammers, UT Southwestern, Dallas, TX, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from MSD. This activity is jointly provided by USF Health and touchIME.